Clinical trial • Phase I • Immunology | Respiratory | Dermatology | Gastroenterology

CKD-706 for Atopic dermatitis | Asthma | Chronic rhinosinusitis with nasal polyposis | Eosinophilic esophagitis | Prurigo nodularis | Chronic obstructive pulmonary disease

Phase I trial of CKD-706 for Atopic dermatitis | Asthma | Chronic rhinosinusitis with nasal polyposis | Eosinophilic esophagitis | Prurigo nodularis | Chr…

Overview

Trial Therapeutic Area
Immunology | Respiratory | Dermatology | Gastroenterology
Trial Disease
Atopic dermatitis | Asthma | Chronic rhinosinusitis with nasal polyposis | Eosinophilic esophagitis | Prurigo nodularis | Chronic obstructive pulmonary disease
Trial Stage
Phase I
Drug Modality
Monoclonal antibody

Key dates

Initial CTIS Submission Date
29-10-2025
First CTIS Authorization Date
09-01-2026

Trial design

CKD-706 compared with US-Dupixent® and EU-Dupixent® (drug names stated; doses and schedules not specified in the provided data)-controlled Phase I trial across 1 site in Germany.

Comparator
CKD-706 compared with US-Dupixent® and EU-Dupixent® (drug names stated; doses and schedules not specified in the provided data)
Target Sample Size
519
Trial Duration For Participant
273

Recruitment

Planned Sample Size
519
Recruitment Window Months
9

Geography

Total Number Of Sites
1
Total Number Of Participants
335

Germany

Earliest CTIS Part Ii Submission Date
11-12-2025
Latest Decision Or Authorization Date
09-01-2026
Processing Time Days
29
Number Of Sites
1
Number Of Participants
335

Sites

Site Name
Klinikum Westend Haus 31, Spandauer Damm 130, Charlottenburg
Department Name
01
Contact Person Name
Camila Rincon
Contact Person Email
Camila.Rincon@parexel.com

Sponsor

Primary sponsor

Full Name
Chong Kun Dang Pharmaceutical Corp.
Organisation Type
Pharmaceutical company
Country Of Registered Address
Korea, Republic of

Contract research organisations

Name
PAREXEL International GmbH
Responsibilities
Site contact / clinical operations (contact provided in trial site record: Camila.Rincon@parexel.com)

Investigational products

Investigational Product Name
CKD-706
Modality
Monoclonal antibody
Investigational Product Name
US-Dupixent®
Modality
Monoclonal antibody
Investigational Product Name
EU-Dupixent®
Modality
Monoclonal antibody

Related trials

Other published trials that may interest you.